Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

(2022) Adam C. Palmer et al.   CLINICAL CANCER RESEARCH

First-Line Immunotherapy for Non–Small-Cell Lung Cancer

(2022) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Platelet Count and Survival after Cancer

(2022) Vasily Giannakeas et al.   Cancers

A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression

(2022) Jung Han Kim et al.   Journal of Clinical Medicine

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

(2021) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

(2021) Ahmet Sezer et al.   LANCET

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

(2021) Margarita Majem et al.   Journal of Clinical Medicine

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

(2021) G.L. Banna et al.   ESMO Open

Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application

(2021) Gang Xiao et al.   Immunotherapy

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

(2021) Oladimeji Akinboro et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

(2021) G. Fornarini et al.   ESMO Open

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

(2021) Liran Holtzman et al.   Clinical Lung Cancer

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

(2021) Giuseppe L. Banna et al.   Thoracic Cancer

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

(2021) G. Mountzios et al.   ESMO Open

Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)

(2020) Hiren Mandaliya et al.   Translational Lung Cancer Research

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

(2020) Lihong Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis

(2020) Na Zhang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

(2020) Nadia Howlader et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis

(2020) Kaili Yang et al.   Frontiers in Oncology

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

(2020) Alessio Cortellini et al.   Journal for ImmunoTherapy of Cancer

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

(2020) Giuseppe Luigi Banna et al.   Translational Lung Cancer Research

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

(2020) Julien Mazieres et al.   Journal of Thoracic Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

(2019) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

(2019) Ugo De Giorgi et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

(2019) Alfredo Addeo et al.   Frontiers in Oncology

Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis

(2019) Yan Wang et al.   Annals of Translational Medicine

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

(2019) Rui Kitadai et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

(2018) Giuseppe Luigi Banna et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice

(2018) Raffaele Califano et al.   Future Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma

(2017) Min-Kyung Yeo et al.   HUMAN PATHOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER